Socioeconomic disparities and survival in paediatric AML

Dr Lena Winestone

Home > Haematology > ASH 2019

Read the full Report (pdf)

American Society of Hematology

7–10 December 2019 Orlando, Florida, USA

Featured articles

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, VU University Medical Center, the Netherlands

Conference

ASH 2019

5 March, 2020 14:27

Online First

Late-Breaking Abstracts

Likely new standard of care: Blinatumomab for children with relapsed B-ALL

Presented By

Prof. Patrick A. Brown, Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Trial

Phase 3, AALL1331

Conference

ASH 2019

5 March, 2020 23:15

Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis

Presented By

Dr Alexander Röth, University of Duisburg-Essen, Germany

Trial

Phase 3, CARDINAL

Conference

ASH 2019

5 March, 2020 22:36

Oral azacitidine improves overall survival in patients with AML in remission

Presented By

Dr Andrew Wei, Alfred Hospital, Australia

Trial

Phase 3, QUAZAR AML-001

Conference

ASH 2019

5 March, 2020 21:39

BCL11A as a novel target in gene therapy for sickle cell disease

Presented By

Dr David Williams, Boston Children’s Hospital, USA

Conference

ASH 2019

5 March, 2020 20:45

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Presented By

Prof. Saad Usmani, UNC-Chapel Hill School of Medicine, USA

Trial

Phase 3, CANDOR

Conference

ASH 2019

5 March, 2020 19:49

Long-term data of ropeginterferon alpha-2b in polycythaemia vera

Presented By

Prof. Jean-Jacques Kiladjian, Saint Louis Hospital, France

Trial

PROUD-PV

Conference

ASH 2019

5 March, 2020 18:53

Anti-CD70 is safe with hypomethylating agents in AML

Presented By

Prof. Adrian Ochsenbein, Bern University Hospital, Switzerland

Conference

ASH 2019

5 March, 2020 17:01

MRD assessment to guide pre-emptive treatment decisions

Presented By

Prof. Uwe Platzbecker, University Hospital Carl Gustav Carus, Germany

Trial

Phase 2, RELAZA2

Conference

ASH 2019

5 March, 2020 16:04

Luspatercept effective for myelofibrosis-associated anaemia

Presented By

Prof. Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, USA

Conference

ASH 2019

5 March, 2020 15:11

Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Presented By

Prof. Gill Singh, University of Hong Kong, China

Conference

ASH 2019

5 March, 2020 14:13

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Presented By

Dr Xiaowen Tang; Dr James Foran

Trial

Socioeconomic disparities and survival in paediatric AML

Presented By

Dr Lena Winestone, UCSF Benioff Children’s Hospital, USA

Trial

Phase 3, AAML0531 and AAML1031

Conference

ASH 2019

5 March, 2020 23:55

Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

Presented By

Dr Christine Chen, Princess Margaret Cancer Centre, University of Toronto, Canada

Trial

MM-003, STOMP

Conference

ASH 2019

5 March, 2020 22:59

CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

Presented By

Dr Karl Kilgore, Avalere, USA

Conference

ASH 2019

5 March, 2020 21:07

Mild renal impairment in African Americans does not affect OS in AML

Presented By

Dr Abby Statler, Cleveland Clinic, USA

Conference

ASH 2019

5 March, 2020 19:10

ALCYONE: New overall survival results for myeloma

Presented By

Dr Maria Victoria Mateos, University Hospital of Salamanca, Spain

Trial

Phase 3, ALCYONE

Conference

ASH 2019

5 March, 2020 16:16

Venous Thromboembolism

Rivaroxaban is safe and effective for paediatric venous thromboembolism

Presented By

Prof. Guy Young, Children's Hospital Los Angeles, USA

Trial

Phase 3, EINSTEIN-Jr

Conference

ASH 2019

5 March, 2020 20:19

Aspirin plus DOAC is not better than a DOAC alone

Presented By

Prof. Jordan Schaefer, University of Michigan, USA

Conference

ASH 2019

5 March, 2020 19:23

20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

Presented By

Dr Maria Vazquez, MD Anderson Cancer Center, Houston, USA

Conference

ASH 2019

5 March, 2020 16:26

CAR T and Beyond

BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

Presented By

Dr Deepu Madduri, Mount Sinai Medical Center, USA

Trial

Phase 1/2, CARTITUDE-1

Conference

ASH 2019

5 March, 2020 20:29

Anti-BCMA/anti-CD38 in refractory multiple myeloma

Presented By

Prof. Yu Hu, Huazhong University of Science and Technology, China

Conference

ASH 2019

5 March, 2020 16:31

Off-the-shelf natural killer cells

Presented By

Dr Jode Goodridge, Fate Therapeutics, USA

Conference

ASH 2019

5 March, 2020 09:38

Featured articles

CONTENTS

Online First

Late-Breaking Abstracts

Sickle Cell Disease

Plenary Scientific Session

Inclusive Medicine

Venous Thromboembolism

CAR T and Beyond